Why at Least One Analyst Isn’t Chasing Neogen

By Chris Lange Updated Apr 28, 10:13AM EDT · Published Sep 21, 3:08PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

178375719 Neogen Corp. (NASDAQ: NEOG) reported its fiscal first-quarter financial results before the markets opened on Monday morning. The company had $0.25 in earnings per share (EPS) on $74.86 million in revenue, compared to consensus estimates from Thomson Reuters of $0.27 in EPS on $76.35 million. The same period from the previous year had $0.24 in EPS on $67.60 million in revenue. In this report, the company reported organic growth of 10%, which contributed to a slight miss on the top and bottom lines.

Despite this miss, Janney believes that Neogen is positioned to continue its strong growth. An expanding international footprint, partnership with Illumina Inc. (NASDAQ: ILMN), passage of rules from the Food Safety Modernization Act (FSMA), and robust demand for rodenticides represent multiple levers to continue driving top-line growth.

In the earnings report, management highlighted the emergence of e-commerce as a meaningful percentage of Food Safety revenue. Representing 10% of Food Safety revenue, up from zero two years ago, e-commerce is particularly appealing to end-users who have a routine order schedule and know exactly what products they need.

DNA Testing growth was lower than Janney estimated at about 12%; however, management noted the recently announced Illumina partnership has not impacted revenue and order lumpiness. The firm believes the partnership will drive penetration in international markets and lead to industry-plus growth. Furthermore, panel pricing has fallen considerably over the past few years and may be stabilizing.

During the quarter, Neogen made two acquisitions, Lab M Holdings and Sterling Test House, for a combined $13 million. While it will be a minor contributor to revenue in the area of $650,000, Sterling represents a launchpad for additional opportunities in India. Management highlighted China and India as two key drivers of future growth.

The firm maintained its fair value estimate of $57 and Neutral rating, implying an upside of 16.25% from current prices.

Shares of Neogen were down 9.5% at $49.03 on Monday afternoon. The stock has a consensus analyst price target of $55.00 and a 52-week trading range of $38.74 to $62.70.

ALSO READ: 9 Analyst Stock Picks Under $10 With Huge Upside Calls

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.